title: Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.
abstract: Forty-three patients with chronic myeloid leukaemia in first chronic phase were recruited to study intensive chemotherapy (idarubicin plus cytarabine; IdAC) followed by collection of peripheral blood stem cells (PBSC) in the recovery phase. PBSC autografting was performed on 32 patients. One patient died during mobilization and three died following autograft. All procedural deaths occurred in patients who received IdAc more than a year from diagnosis. Nine further patients died, eight following progression of CML. 72% of transplanted patients showed a major cytogenetic response but most cases have returned to Philadelphia-positive haemopoiesis. 62% of autografted patients remain alive (median survival from diagnosis 52 months). Four of the 11 patients who did not receive a transplant remain in chronic phase.
authors.affiliation: Glasgow Royal Infirmary.
authors.forename: I O
authors.initials: IO
authors.lastname: Singer
authors.forename: I M
authors.initials: IM
authors.lastname: Franklin
authors.forename: R E
authors.initials: RE
authors.lastname: Clark
authors.forename: E A
authors.initials: EA
authors.lastname: Chalmers
authors.forename: S M
authors.initials: SM
authors.lastname: Kelsey
authors.forename: A C
authors.initials: AC
authors.lastname: Newland
authors.forename: A M
authors.initials: AM
authors.lastname: Sproul
authors.forename: G
authors.initials: G
authors.lastname: Crotty
authors.forename: S R
authors.initials: SR
authors.lastname: McCann
authors.forename: A H
authors.initials: AH
authors.lastname: Goldstone
authors.forename: N
authors.initials: N
authors.lastname: McBride
authors.forename: A
authors.initials: A
authors.lastname: Hepplestone
authors.forename: W
authors.initials: W
authors.lastname: Watson
authors.forename: R A
authors.initials: RA
authors.lastname: Sharp
authors.forename: P J
authors.initials: PJ
authors.lastname: Tansey
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002066:Busulfan / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D018450:Disease Progression; D005500:Follow-Up Studies; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D016898:Interferon-alpha / Q000627:therapeutic use; D015466:Leukemia, Myeloid, Chronic-Phase / Q000628:therapy*; D008875:Middle Aged; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D003561:Cytarabine; D002066:Busulfan; D015255:Idarubicin